Evidence map›Paper›PMID 38398832›Full record

ArticleNutrients2024

Kaempferol Improves Cardiolipin and ATP in Hepatic Cells: A Cellular Model Perspective in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Akiko Sakurai, Toshihiro Sakurai, Hsin-Jung Ho, Hitoshi Chiba, Shu-Ping Hui

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Akiko SakuraiFaculty of Health Sciences, Hokkaido University, Sapporo 060-0812, Japan.
Toshihiro SakuraiFaculty of Health Sciences, Hokkaido University, Sapporo 060-0812, Japan.ORCID 0000-0003-1759-3802
Hsin-Jung HoFaculty of Health Sciences, Hokkaido University, Sapporo 060-0812, Japan.ORCID 0000-0001-8421-4919
Hitoshi ChibaDepartment of Nutrition, Sapporo University of Health Sciences, Sapporo 007-0894, Japan.ORCID 0000-0003-4640-7730
Shu-Ping HuiFaculty of Health Sciences, Hokkaido University, Sapporo 060-0812, Japan.ORCID 0000-0001-9973-6461
Sapporo University · JP

Funding

the Japan Society for the Promotion of Science, KAKENHI 19K20174the Japan Society for the Promotion of Science, KAKENHI 22K11797
6 · The paper itself

Abstract

Targeting mitochondrial function is a promising approach to prevent metabolic dysfunction-associated steatotic liver disease (MASLD). Cardiolipin (CL) is a unique lipid comprising four fatty acyl chains localized in the mitochondrial inner membrane. CL is a crucial phospholipid in mitochondrial function, and MASLD exhibits CL-related anomalies. Kaempferol (KMP), a natural flavonoid, has hepatoprotective and mitochondrial function-improving effects; however, its influence on CL metabolism in fatty liver conditions is unknown. In this study, we investigated the effects of KMP on mitochondrial function, focusing on CL metabolism in a fatty liver cell model (linoleic-acid-loaded C3A cell). KMP promoted mitochondrial respiratory functions such as ATP production, basal respiration, and proton leak. KMP also increased the gene expression levels of

Indexed as

CardiolipinsFatty LiverAdenosine TriphosphateHepatocytesHumansKaempferolsAdenosine TriphosphateCardiolipinsKaempferolsATPlipidomicsliquid chromatography/mass spectrometrymetabolic dysfunction-associated steatohepatitismetabolic dysfunction-associated steatotic liver diseasemonolysocardiolipin

Identifiers

PMID38398832
PMCPMC10892986
OpenAlexW4391753906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.